Naivex
Naivex contains Dolutegravir (50mg), which is an integrase strand transfer inhibitor (INSTI). It blocks the integrase enzyme, preventing the HIV virus from replicating and decreasing the viral load in the body, thereby helping to improve the immune system.
Dosage by Body Weight
The standard dose for adults and pediatric patients weighing at least 20 kg is one 50 mg tablet once daily. Dose may be increased to 50 mg twice daily in patients with documented integrase inhibitor resistance or when co-administered with certain drugs (like rifampicin, carbamazepine, or phenytoin). Take with or without food.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Naivex 50mg tablets are not suitable for children in this weight range. Requires specialist pediatric assessment and dispersible formulations.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Naivex 50mg tablets cannot be accurately split for this weight. Requires pediatric-specific dispersible formulations.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Standard 50mg tablet is not suitable. Lower dose dispersible tablets are required for pediatric patients under 14-20 kg.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Standard 50mg tablet is generally not recommended unless specified by a specialist for patients close to 14-15 kg using pediatric strength formulations.
- Body Weight
- 16-20 kg
- Dose
- 50 mg
- Frequency
- Once daily
- Tracking Notes
- Only appropriate for children weighing at least 20 kg. For children 14 kg to < 20 kg, alternative lower-strength formulations are preferred.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Naivex 50mg tablets are not suitable for children in this weight range. Requires specialist pediatric assessment and dispersible formulations. |
| 5-7 kg | Not recommended | N/A | Naivex 50mg tablets cannot be accurately split for this weight. Requires pediatric-specific dispersible formulations. |
| 8-10 kg | Not recommended | N/A | Standard 50mg tablet is not suitable. Lower dose dispersible tablets are required for pediatric patients under 14-20 kg. |
| 11-15 kg | Not recommended | N/A | Standard 50mg tablet is generally not recommended unless specified by a specialist for patients close to 14-15 kg using pediatric strength formulations. |
| 16-20 kg | 50 mg | Once daily | Only appropriate for children weighing at least 20 kg. For children 14 kg to < 20 kg, alternative lower-strength formulations are preferred. |
Formulation
Purpose
Treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in combination with other antiretroviral agents.
Generic Name
DolutegravirScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.